Immunocore Open menu Partners Recognising the value of collaboration Home / About us / Partners In addition to a well-established pipeline of wholly-owned programmes, Immunocore's transformational science has led to multi-target discovery partnerships with Genentech, Eli Lilly, and GlaxoSmithKline to develop new cancer therapies using the ImmTAC® technology platform. Both the Genentech and Eli Lilly partnerships include a co-development/co-promotion arrangement in addition to ImmTAC® molecule co-discovery. Outside of oncology, the Bill and Melinda Gates Foundation is supporting the expansion of Immunocore's technology platform to develop ImmTAV®/ImmTAB® molecules for the treatment of infectious diseases, including HIV. In addition, the Juvenile Diabetes Research Foundation is partnering with Immunocore on our type 1 diabetes program. Please direct any partnering inquiries to: partnering@immunocore.com IN THIS SECTION About us Management team Board of Directors Immunocore About us Our science Our therapy areas For patients Investors/Media Careers Contact us Privacy and Social Media Guidelines Cookies Payments and Disclosures Clinical trials Gender Pay Report ©2021 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd To offer you a better experience, this site uses cookies, including those of third parties. To find out more and manage your preferences, consult the Cookie notice I Accept

Immunocore Open menu Our therapy areas Pioneering T cell receptor innovation Home / Our therapy areas Immunocore is a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that will have the potential to transform the lives of people with serious diseases. Immunocore has a robust clinical-stage pipeline of wholly-owned and partnered programmes across three different therapeutic areas: Oncology Molecules in development ImmTAC (Immune Mobilizing Monoclonal TCRs Against Cancer) molecules Infectious Diseases Molecules in development ImmTAV and ImmTAB (Immune Mobilizing Monoclonal TCRs Against Virus or Bacteria) molecule Autoimmune and Inflammation diseases Molecules in development ImmTAAI (Immune Mobilizing Monoclonal TCRs Against Autoimmune Disease) molecule IN THIS SECTION Oncology Infectious Diseases Autoimmune and Inflammation diseases Immunocore About us Our science Our therapy areas For patients Investors/Media Careers Contact us Privacy and Social Media Guidelines Cookies Payments and Disclosures Clinical trials Gender Pay Report ©2021 Immunocore, Ltd. All rights reserved. ImmTAC, ImmTAV, ImmTAB, ImmTAAI and ImmTAX are all registered trademarks of Immunocore, Ltd To offer you a better experience, this site uses cookies, including those of third parties. To find out more and manage your preferences, consult the Cookie notice I Accept